Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.89 +0.79%

+$0.03 today

Market cap
$169.16M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.16M

Average 0.16M

ORMP Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Oramed Pharmaceuticals Inc.NASDAQ: ORMP

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures grows, but more slowly than its trailing trend

Q1 FY2026 capital expenditures of $5K (cash outflow) rose 66.7% year over year, behind the +1114.8% change in trailing-twelve-month capital expenditures. Over 3 fiscal years it compounded at +57.4% a year.

Context

  • Capital expenditures amounted to 96.7% of revenue in FY2025.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +66.7% toward the trailing-twelve-month pace of +1114.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5K-102.5% QoQ
Last fiscal yearDec 2025
-$1.93M+10639.5% YoY
LTMMar 2026
$192.68K+1114.8% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+66.7%——
1 year+10639.5%——
3-year CAGR+57.4%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(1.93M) USD
Year-over-year change
-10639.5%

Capital Expenditures vs competitors

How ORMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1114.8% is the highest of 8, against a peer median of -9.7%.
  • Over three fiscal years its annual growth of +57.4% compares with a peer median of -56.8%.
ORMP Competitors
Capital Expenditures for ORMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STTKShattuck Labs, Inc.LTM Mar 2026$10.42M USD-12.9%-81.7%1042.3%
MGNXMacroGenics, Inc.LTM Mar 2026$1.73M USD-37.7%-19.2%1.1%
CNTBConnect Biopharma Holdings LimitedFY2025$434K USD-42.1%-53.4%678.1%
KLRSKalaris Therapeutics IncLTM Mar 2026$200K USD———
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$192.68K USD+1114.8%+57.4%—
IFRXInflaRx N.V.LTM Mar 2026€114.87K EUR+178.5%-11.9%391.6%
CLNNClene Inc.LTM Mar 2026$39K USD+874.9%-80.4%29.1%
CNTXContext Therapeutics Inc.LTM Mar 2026$37.26K USD-9.7%-60.2%—
COYACoya Therapeutics, Inc.LTM Mar 2026$3 USD——0.0%
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 USD+100.0%—0.0%
IMAImageneBio IncLTM Mar 2026$0 USD———
Peer median (excluding ORMP) —-9.7%-56.8%29.1%

Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(22.24M)(36.56M)5.53M(19.06M)64.02M
Depreciation & Amortization77K58K196K193K121K
Deferred Income Tax00007.91M
Stock-Based Compensation00005.99M
Change in Working Capital(1.32M)(943K)(2.7M)3.2M(1.91M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.06M(376K)(2.23M)3.53M1.13M
Other Working Capital(3.38M)(567K)(471K)(325K)(3.04M)
Other Non-Cash Items2.3M8.75M(13.32M)7.26M(85.28M)
Operating Cash Flow(21.18M)(28.7M)(10.3M)(8.41M)(9.15M)
Capital Expenditures(375K)(496K)(254K)(18K)(1.93M)
Acquisitions (Net)1.5M24K00(7.25M)
Purchases of Investments(53.82M)(154.41M)(190.92M)(55.76M)(88.51M)
Sales of Investments30.43M185.09M118.14M161.65M96.88M
Other Investing Activities(1K)2K0(60K)6.25M
Investing Cash Flow(22.26M)30.21M(73.04M)105.82M5.44M
Debt Repayment——49.55M(49.55M)0
Common Stock Issued101.39M11.56M2.43M00
Common Stock Repurchased000(2.48M)(4.74M)
Dividends Paid00000
Other Financing Activities000(2K)0
Financing Cash Flow101.39M11.56M51.98M(52.04M)(4.74M)
Effect of Forex Changes2K(49.85M)(54K)(4K)(30K)
Net Change in Cash57.95M(36.78M)(31.41M)45.37M(8.47M)
Free Cash Flow(21.56M)(29.2M)(10.55M)(8.43M)(11.08M)

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Intrinsic Alpha fair value

Locked

Current Price

$3.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.